Eli Lilly (LLY) Higher on Alzheimer Drug Hopes, Though Results Fail to Impress Analysts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly (LLY) Moves Higher on Large Block Trade
October 9, 2012 9:55 AM EDTEli Lilly & Co. (NYSE: LLY) on th move as a 1.14 million share block trade pushed the stock above $51.55 today.
Overall, Lilly shares are up 1.8 percent Tuesday, following a 5.3 percent run yesterday on new EXPEDITION data.
Average volume for Lilly is about 7.5 million shares.... More
Goldman Sachs Upgrades Eli Lilly (LLY) to Neutral on New "Hope Trade"
October 9, 2012 7:01 AM EDTGoldman Sachs upgraded Eli Lilly (NYSE: LLY) from Sell to Neutral with a price target of $54.00 (from $42.00) saying the Sola data supports optionality trade.
New solanezumab data provides a backbone for the recent "hope trade," the firm notes.
"Our... More
Lilly (LLY) Updates on EXPEDITION in Alzheimer's; Slowing Observed in Pooled Analysis
October 8, 2012 1:18 PM EDTEli Lilly and Company (NYSE: LLY) announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease. This announcement follows the presentation of results from independent analyses of the EXPEDITION study data conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic research consortium, at the annual meeting of the American Neurological Association (ANA) by Rachelle Doody, M.D., Ph.D., professor of Neurology and the Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine. Dr. Doody is a member of the steering... More
